1. Scrip
  2. >>New Products

Imfinzi Adds Approval In Early-Stage Lung Cancer, Matching Keytruda

 
• By Joseph Haas

AstraZeneca is working to bolster its PD-L1 agent’s applicability in resectable non-small cell lung cancer, seeking advantages versus Merck’s Keytruda and Bristol’s Opdivo.

AZN
AstraZeneca adds early-stage lung cancer perioperative indication to Imfinzi's label • Source: Shutterstock

Despite a complicated advisory committee review in July, AstraZeneca PLC obtained supplemental US Food and Drug Administration approval on 16 August for its PD-L1 inhibitor Imfinzi for perioperative treatment in resectable non-small cell lung cancer (NSCLC) meeting certain requirements, putting its drug on an equal footing in that setting with Merck & Co., Inc.'s Keytruda and ahead of Bristol Myers Squibb Company’s Opdivo.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

Akeso Wins US Approval For PD-1 Antibody In NPC, Partly On US Data

 
• By Dexter Jie Yan

Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies